Caribou Biosciences (NASDAQ:CRBU – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Caribou Biosciences to related companies based on the strength of its analyst recommendations, profitability, risk, earnings, dividends, valuation and institutional ownership.
Profitability
This table compares Caribou Biosciences and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Caribou Biosciences | -1,085.00% | -102.74% | -69.45% |
| Caribou Biosciences Competitors | -12,224.09% | -202.33% | -31.23% |
Analyst Recommendations
This is a breakdown of recent ratings for Caribou Biosciences and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Caribou Biosciences | 1 | 4 | 1 | 1 | 2.29 |
| Caribou Biosciences Competitors | 9923 | 15317 | 45692 | 1603 | 2.54 |
Caribou Biosciences presently has a consensus target price of $4.50, suggesting a potential upside of 1,174.79%. As a group, “Biotechnology” companies have a potential upside of 131.47%. Given Caribou Biosciences’ higher possible upside, equities research analysts clearly believe Caribou Biosciences is more favorable than its competitors.
Insider and Institutional Ownership
77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Caribou Biosciences and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Caribou Biosciences | $9.44 million | -$148.12 million | -0.34 |
| Caribou Biosciences Competitors | $768.41 million | $11.71 million | -18.32 |
Caribou Biosciences’ competitors have higher revenue and earnings than Caribou Biosciences. Caribou Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Caribou Biosciences has a beta of 2.5, indicating that its share price is 150% more volatile than the S&P 500. Comparatively, Caribou Biosciences’ competitors have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.
Summary
Caribou Biosciences beats its competitors on 7 of the 13 factors compared.
About Caribou Biosciences
Caribou Biosciences, Inc. is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. Its work focuses on allogeneic, or donor-derived, CAR-T cell treatments designed to be manufactured for use by multiple patients. The company uses its chRDNA genome-editing platform, which combines CRISPR RNA with DNA components, to make targeted changes to cells. Its clinical programs include CAR-T candidates directed at targets such as CD19 and BCMA, which are being developed for certain blood cancers.
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
